查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511948

药物安全检测市场规模、份额和趋势分析报告：按产品生命週期、按服务供应商、按类型、按治疗领域、按工艺流程、按最终用途、按地区、细分市场预测，2024-2030 年

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 295 Pages | 商品交期: 2-10个工作天内

价格

药物安全检测市场的成长与趋势：

Grand View Research, Inc. 的最新报告显示，到 2030 年，全球药物安全检测市场规模预计将达到 117.8 亿美元。

预计2024年至2030年复合年增长率为6.8%。市场成长的主要驱动力是药物不良反应（ADR）发生率的增加。药品不良反应给医疗保健系统带来了沉重负担，并且是已开发国家发病率的明显来源之一。根据美国国家生物技术资讯中心 (NCBI) 的数据，欧洲每年约有二十分之一的住院患者是由于 ADR 引起的。药物安全检测(PV) 服务在临床试验阶段发挥重要作用，帮助製造商识别与药物相关的不良反应。

此外，2022 年 2 月发表在《当代医学研究与实践杂誌》上的一篇论文，题为“接受癌症化疗药物的患者不良药物反应的严重性和结果——一项前瞻性观察研究”，根据「不良药物不良反应的严重性和结果」不良 ADR 患者的结果特征 - 一项前瞻性观察研究表明，严重的ADR 每年在美国导致超过100,000 人死亡，并且在过去十年中已成为主要的健康问题。致命性心律不整和肝功能衰竭等不良反应可能导致药物从市场上撤出，因为与其使用相关的风险超过了相关的益处。 COVID-19 大流行为光电服务供应商带来了机会和挑战，促进了创新平台的发展，以提高其竞争力。

例如，2020年12月，生命科学产业商业服务供应商EVERSANA与专门从事药物开发流程自动化的生命科学软体公司ArisGlobal合作。该合作伙伴关係旨在将端到端PV程序数位化，并在全球范围内实现更安全、更有效的医疗保健。技术先进且用户友好的软体系统市场，如云端基础的光伏和药物安全平台，预计将在预测期内支援产业成长。例如，Clinevo Technologies 提供 Clinevo Safety，这是一种云端基础的解决方案，涵盖案例处理、监管提交/AS2 网关、PV 摄取、分析、安全讯号和其他功能。

这一一体化平台正在推动市场发展。此外，有组织的努力正在支持巴西等新兴市场的成长。例如，巴西推出了一项涉及製药业、学术界、临床实践和卫生当局的病患安全和 PV 计画。该计画由 FIPFARMA（Fundacao Instituto de Pesquisas Farmaceuticas）和药学院（圣保罗大学）提供，并分两批（2020 年和 2022 年）开展了 30 小时的线上课程。本课程涵盖了重要主题，例如医疗保健和药物安全检测概述、药物安全和管理以及病人安全文化。研讨会解决了医疗保健专业人员 (HCP) 面临的现实挑战，并鼓励协作解决问题。

视讯会议有效地吸引了医护人员并对其进行了教育，促进了知识共用，并鼓励了心态转变。这项措施对参与者产生了积极影响，加强了巴西的光伏实践。已开发国家的主要製药公司都将重点放在外包光电服务上，以降低成本并减少营运费用。预计这将为开发中国家的 CRO（委外研发机构）创造扩大其行业份额的机会。製造商正在重新考虑产品开发程序，以满足全球患者不断增长的需求。由于这些因素，光伏服务的需求预计在预测期内将会成长。

此外，光伏产业的公司正在实施收购、合作、扩张和产品发布等策略，以扩大其产品范围并提高市场占有率。例如，专门从事製药业的服务供应商Ergomed plc 于 2022 年 2 月收购了 ADAMAS Consulting Group Limited。 ADAMAS 是一家国际顾问公司，为药品製造、临床试验审核和光电系统提供品质保证服务。此次收购价值 2,560 万英镑，预计将为 Ergomed 的收益带来正面影响，预计未来将获得进一步成长和战略优势。

药物安全检测市场报告亮点

  • 2023年，第四期将占据市场主导地位，收益占有率将超过75.85%。这是由于 ADR 事件和上市后监督的增加。
  • 由于医药企业旨在透过外包服务降低业务成本，2023年服务供应商产业外包市场占有率超过60.63%。
  • 自我报告细分市场在 2023 年以超过 30.22% 的销售份额引领市场。其应用包括高效且经济高效地检测新型、严重和罕见的 ADR。
  • 在生物製药公司在慢性癌症治疗方面的研究努力的推动下，2023年的治疗领域中，肿瘤学占最大份额，超过26.95%。
  • 预计在预测期内，案例资料管理将以流程领域中最快的复合年增长率成长 7.3%。
  • 在最终用途领域，生技公司预计将以 8.0% 的最快复合年增长率成长。这是由于我们专注于生技药品、疗法和基因疗法等新产品的研究和开发。
  • 由于对开发新药的投资、有利的法规以及强大的研究单位和临床试验的存在，北美在 2023 年占据了最大的销售份额，超过 32.55%。
  • 公司采用新产品发布、联盟和收购等策略来获得竞争优势。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章药物安全检测市场变数、趋势、范围

  • 市场体系展望
    • 母市场分析
    • 辅助市场分析
  • 渗透率和成长前景图
  • 药物安全检测市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 产业挑战
  • 药物安全检测市场分析工具：Porter
  • SWOT 分析，按因素（政治/法律、经济、技术）
  • 价值链分析
    • 临床前
    • 临床
    • PMA
  • 绘製服务交付和需求的生命週期
  • 法律规范
    • 按国家/地区分類的监管机构列表
  • 组织架构简介
  • 定价模式
    • 按活动分類的药品安全预算分配
    • 按发展阶段分
    • 按治疗区域
    • 价格水平
  • 技术时间表概述
    • 技术变革与采用
  • COVID-19 的影响
    • 近期趋势和策略成就
    • 公司实施的策略
  • 市场趋势
    • 资源扩展
    • 药物安全检测自动化
  • 通货膨胀的影响
  • 医学写作与医疗安全评论的比较分析
    • 2022年医学写作市场展望
    • 2022 年医疗安全审查市场展望

第四章药物安全检测市场：依产品生命週期估算与趋势分析

  • 2022 年及 2030 年按产品生命週期分類的市场占有率分析
  • 产品生命週期仪表板
  • 市场定义和范围

第五章药物安全检测市场：服务供应商估计与趋势分析

  • 2023年及2030年服务供应商的市场占有率分析
  • 服务供应商仪表板
  • 市场定义和范围

第六章药物安全检测市场：按类型估计和趋势分析

  • 2023 年和 2030 年按类型分類的市场占有率分析
  • 类型仪表板
  • 市场定义和范围

第七章药物安全检测市场：依製程流程估算与趋势分析

  • 2023 年和 2030 年按工艺流程分類的市场占有率分析
  • 流程仪表板
  • 市场定义和范围

第八章药物安全检测市场：按治疗领域估计和趋势分析

  • 2023 年和 2030 年按治疗领域分類的市场占有率分析
  • 治疗区域仪表板
  • 市场定义和范围

第九章药物安全检测市场：最终用途的估计和趋势分析

  • 2023 年和 2030 年按最终用途分類的市场占有率分析
  • 最终使用仪表板
  • 市场定义和范围

第10章药物安全检测市场：按地区、产品、服务供应商、类型和最终用途进行的估计和趋势分析

  • 区域市场简介
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第十一章药物安全检测市场：竞争分析

  • 市场参与分类
  • 上市公司
  • 私人公司
  • 竞争因素和策略
  • 使用药物安全检测服务的医疗保健公司

第十二章竞争格局

  • 公司简介
    • ACCENTURE
    • CLINQUEST GROUP BV（LINICAL AMERICAS）
    • IQVIA Inc.
    • COGNIZANT
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • IBM
    • ARISGLOBAL
    • ICON PLC.
    • CAPGEMINI
    • ITCLINICAL
    • TAKE SOLUTIONS LIMITED
    • PAREXEL INTERNATIONAL CORPORATION.
    • BIOCLINICA, INC.
    • WIPRO
    • UNITED BIOSOURCE LLC
    • FMD K&L（CLINCHOICE）

第13章成功策略

  • 关键成功/评分标准
    • 按类别
  • 选择供应商的关键因素
    • 按类别
    • 按公司规模

第14章转换成本分析

Product Code: 978-1-68038-327-0

Pharmacovigilance Market Growth & Trends:

The global pharmacovigilance market size is projected to reach USD 11.78 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 6.8% from 2024 to 2030. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights:

  • Phase IV dominated the market with a revenue share of over 75.85% in 2023. This was driven by increased ADR incidents and post-marketing surveillance
  • Contract outsourcing accounted for over 60.63% market share in the service provider segment in 2023, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
  • The spontaneous reporting type segment led the market with a revenue share of over 30.22% in 2023. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
  • Oncology held the largest share of over 26.95% in the therapeutic area segment in 2023, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
  • Case data management is anticipated to grow at the fastest CAGR of 7.3% in the process flow segment during the forecast period
  • Biotechnology companies are expected to have the fastest CAGR of 8.0% in the end-use segment. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
  • North America held the largest revenue share of over 32.55% in 2023 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
  • Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product Life Cycle
    • 1.1.2 Service Provider
    • 1.1.3 Type
    • 1.1.4 Process Flow
    • 1.1.5 Therapeutic Area
    • 1.1.6 End Use
    • 1.1.7 Regional Scope
    • 1.1.8 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details Of Primary Research
      • 1.3.5.1 Data for primary interviews in North America
      • 1.3.5.2 Data for Primary Interviews in Europe
      • 1.3.5.3 Data for Primary Interviews in Asia Pacific
      • 1.3.5.4 Data for Primary Interviews in Latin America
      • 1.3.5.5 Data for Primary Interviews in Middle East & Africa
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Top down market estimation
      • 1.6.1.2 CAGR Calculation
      • 1.6.1.3 Key Report Updates
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Market Definitions
  • 1.10 Report Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot (Product Life Cycle & Service Provider)
  • 2.3 Segment Snapshot (Type & Therapeutic Area)
  • 2.4 Segment Snapshot (Process Flow & End Use)
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Analysis
    • 3.1.2 Ancillary Market Analysis
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Pharmacovigilance Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Growing drug consumption and drug development rates
      • 3.3.1.2 Increasing incidence of ADR and drug toxicity
      • 3.3.1.3 Increasing trend of outsourcing pharmacovigilance services
      • 3.3.1.4 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 3.3.1.5 Increasing regulatory Burden on Manufacturers
      • 3.3.1.6 Introduction of technologically advanced software services
      • 3.3.1.7 Constantly rising investment on R&D by healthcare companies
      • 3.3.1.8 Partnerships and collaborations between market players
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Shortage of skilled labor
      • 3.3.2.2 Expensive technology for small and mid-sized player
      • 3.3.2.3 Lack of recognition
      • 3.3.2.4 Scarcity of integration standards
    • 3.3.3 Industry Challenges
  • 3.4 Pharmacovigilance Market Analysis Tools: Porters
  • 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
  • 3.6 Value Chain Analysis
    • 3.6.1 Preclinical
    • 3.6.2 Clinical
    • 3.6.3 PMA
  • 3.7 Mapping of Life Cycle against Service Offering and Their Demand
  • 3.8 Regulatory Framework
    • 3.8.1 List of Regulatory Bodies by Country
  • 3.9 Organization Structure Introduction
  • 3.10 Pricing Models
    • 3.10.1 Drug Safety Budget Allocation by Activities
    • 3.10.2 By Development Phase
    • 3.10.3 By Therapeutic Area
    • 3.10.4 Pricing Level
      • 3.10.4.1 Project management
      • 3.10.4.2 Case processing
      • 3.10.4.3 ADR Reporting
      • 3.10.4.4 Medical writing
      • 3.10.4.5 Drug safety management
  • 3.11 Technology Timeline Overview
    • 3.11.1 Changing Technology & Adoption
      • 3.11.1.1 Social Media
      • 3.11.1.2 Literature screening
      • 3.11.1.3 Automation and AI
      • 3.11.1.4 Big data analytics in PV
  • 3.12 Impact of COVID-19
    • 3.12.1 Recent Developments & Strategic Outcomes
      • 3.12.1.1 Regulatory requirements/changes due to covid-19
    • 3.12.2 Strategies Implemented by Companies
      • 3.12.2.1 IQVIA
      • 3.12.2.2 PARAXEL International Corporation
      • 3.12.2.3 Bioclinica
      • 3.12.2.4 Pharmaceutical Product Development (PPD)
      • 3.12.2.5 IBM Corporation
      • 3.12.2.6 ICON, plc
      • 3.12.2.7 PRA Health Sciences
      • 3.12.2.8 Covance Inc.
      • 3.12.2.9 ArisGlobal
      • 3.12.2.10 Linical Accelovance
      • 3.12.2.11 Laboratory Corporation of America Holdings
  • 3.13 Market Trends
    • 3.13.1 Scaling Of Resources
    • 3.13.2 Automation in Pharmacovigilance
  • 3.14 Impact of Inflation
  • 3.15 Comparative Analysis between Medical Writing vs Medical Safety Review
    • 3.15.1 Medical Writing Market Outlook, 2022
      • 3.15.1.1 Medical writing Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 3.15.2 Medical Safety Review Market Outlook, 2022
      • 3.15.2.1 Medical Safety Review market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 4 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

  • 4.1 Product Life Cycle Market Share Analysis, 2022 & 2030
  • 4.2 Product Life Cycle Dashboard
  • 4.3 Market definition and scope
    • 4.3.1 Preclinical
      • 4.3.1.1 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.2 Phase I
      • 4.3.2.1 Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.3 Phase II
      • 4.3.3.1 Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.4 Phase III
      • 4.3.4.1 Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.5 Phase IV
      • 4.3.5.1 Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

  • 5.1 Service provider Market Share Analysis, 2023 & 2030
  • 5.2 Service Provider Dashboard
  • 5.3 Market definition and scope
    • 5.3.1 IN HOUSE
      • 5.3.1.1 In house market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.2 Contract Outsourcing
      • 5.3.2.1 Contract outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 6.1 Type Market Share Analysis, 2023 & 2030
  • 6.2 Type Dashboard
  • 6.3 Market definition and scope
    • 6.3.1 Spontaneous Reporting
      • 6.3.1.1 Spontaneous Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2 Intensified ADR Reporting
      • 6.3.2.1 Intensified ADR Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3 Targeted Spontaneous Reporting
      • 6.3.3.1 Targeted spontaneous reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.4 Cohort Event Monitoring (CEM)
      • 6.3.4.1 CEM market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5 EHR Mining
      • 6.3.5.1 EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

  • 7.1 Process Flow Market Share Analysis, 2023 & 2030
  • 7.2 Process Flow Dashboard
  • 7.3 Market definition and scope
    • 7.3.1 Case Data Management
      • 7.3.1.1 Case data management market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1 Case logging
      • 7.3.1.1.1.1 Case logging market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.2 Case data analysis
      • 7.3.1.1.2.1 Case data analysis market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.3 Medical reviewing and reporting
      • 7.3.1.1.3.1 Medical reviewing and reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Signal Detection
      • 7.3.2.1 Signal detection market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.1 Adverse event logging
      • 7.3.2.1.1.1 Adverse Event Logging market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.2 Adverse Event Analysis
      • 7.3.2.1.2.1 Adverse Event Analysis market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.3 Adverse Event Review & Reporting
      • 7.3.2.1.3.1 Adverse Event Review & Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 Risk Management System
      • 7.3.3.1 Risk Management System market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.1 Risk Evaluation System
      • 7.3.3.1.1.1 Risk Evaluation System market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.2 Risk Mitigation System
      • 7.3.2.1.2.1 Risk Mitigation System market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1 Therapeutic Area Market Share Analysis, 2023 & 2030
  • 8.2 Therapeutic Area Dashboard
  • 8.3 Market definition and scope
    • 8.3.1 Oncology
      • 8.3.1.1 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.2 Neurology
      • 8.3.2.1 Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.3 Cardiology
      • 8.3.3.1 Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.4 Respiratory Systems
      • 8.3.4.1 Respiratory systems market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.5 Others
      • 8.3.5.1 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9 Pharmacovigilance Market: End Use Estimates & Trend Analysis

  • 9.1 End Use Market Share Analysis, 2023 & 2030
  • 9.2 End Use Dashboard
  • 9.3 Market definition and scope
    • 9.3.1 Pharmaceuticals
      • 9.3.1.1 Pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 Biotechnology Companies
      • 9.3.2.1 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.3 Medical Device Manufacturers
      • 9.3.3.1 Medical Device Manufacturers market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.4 Others
      • 9.3.4.1 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, and End Use

  • 10.1 Regional Market Snapshot
  • 10.2 North America
    • 10.2.1 North America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.2.2 U.S.
      • 10.2.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
      • 10.2.2.2 Competitive scenario
      • 10.2.2.3 Regulatory Framework
    • 10.2.3 Canada
      • 10.2.3.1 Canada Pharmacovigilance market estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.2.3.2 Competitive scenario
      • 10.2.3.3 Regulatory Framework
  • 10.3 Europe
    • 10.3.1 Europe Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.2 UK
      • 10.3.2.1 UK Pharmacovigilance market estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.2.2 Competitive scenario
      • 10.3.2.3 Regulatory Framework
    • 10.3.3 Germany
      • 10.3.3.1 Germany Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million
      • 10.3.3.2 Competitive scenario
      • 10.3.3.3 Regulatory Framework
    • 10.3.4 France
      • 10.3.4.1 France Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
      • 10.3.4.2 Competitive scenario
      • 10.3.4.3 Regulatory Framework
    • 10.3.5 Italy
      • 10.3.5.1 Italy Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
      • 10.3.5.2 Competitive scenario
      • 10.3.5.3 Regulatory Framework
    • 10.3.6 Spain
      • 10.3.6.1 Spain pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
      • 10.3.6.2 Competitive scenario
      • 10.3.6.3 Regulatory Framework
    • 10.3.7 Russia
      • 10.3.7.1 Russia Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
      • 10.3.7.2 Competitive scenario
      • 10.3.7.3 Regulatory Framework
    • 10.3.8 Denmark
      • 10.3.8.1 Denmark Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.8.2 Competitive scenario
      • 10.3.8.3 Regulatory Framework
    • 10.3.9 Norway
      • 10.3.9.1 Norway Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.9.2 Competitive scenario
      • 10.3.9.3 Regulatory Framework
    • 10.3.10 Sweden
      • 10.3.10.1 Sweden Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.10.2 Competitive scenario
      • 10.3.10.3 Regulatory Framework
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.2 JAPAN
      • 10.4.2.1 Japan Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.2.2 Competitive scenario
      • 10.4.2.3 Regulatory Framework
    • 10.4.3 CHINA
      • 10.4.3.1 China Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.3.2 Competitive Scenario
      • 10.4.3.3 Regulatory Framework
    • 10.4.4 India
      • 10.4.4.1 India Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.4.2 Competitive Scenario
      • 10.4.4.3 Regulatory Framework
    • 10.4.5 Australia
      • 10.4.5.1 Australia Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.5.2 Competitive Scenario
      • 10.4.5.3 Regulatory Framework
    • 10.4.6 Thailand
      • 10.4.6.1 Thailand Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.6.2 Competitive Scenario
      • 10.4.6.3 Regulatory Framework
    • 10.4.7 South Korea
      • 10.4.7.1 South Korea Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.7.2 Competitive Scenario
      • 10.4.7.3 Regulatory Framework
  • 10.5 Latin America
    • 10.5.1 Latin America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.2 Brazil
      • 10.5.2.1 Brazil Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.5.2.2 Competitive Scenario
      • 10.5.2.3 Regulatory Framework
    • 10.5.3 Mexico
      • 10.5.3.1 Mexico Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.5.3.2 Competitive Scenario
      • 10.5.3.3 Regulatory Framework
    • 10.5.4 Argentina
      • 10.5.4.1 Argentina Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.5.4.2 Competitive Scenario
      • 10.5.4.3 Regulatory Framework
  • 10.6 MEA
    • 10.6.1 MEA Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.6.2 South Africa
      • 10.6.2.1 South Africa Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.6.2.2 Competitive Scenario
      • 10.6.2.3 Regulatory Framework
    • 10.6.3 Saudi Arabia
      • 10.6.3.1 Saudi Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
      • 10.6.3.2 Competitive Scenario
      • 10.6.3.3 Regulatory Framework
    • 10.6.4 UAE
      • 10.6.4.1 UAE Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
      • 10.6.4.2 Competitive Scenario
      • 10.6.4.3 Regulatory Framework
    • 10.6.5 Kuwait
      • 10.6.5.1 Kuwait Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
      • 10.6.5.2 Competitive Scenario
      • 10.6.5.3 Regulatory Framework

Chapter 11 Pharmacovigilance Market: Competitive Analysis

  • 11.1 Market Participation Categorization
  • 11.2 Public Companies
    • 11.2.1 Company Market Position Analysis
    • 11.2.2 Company Market Share
  • 11.3 Private Companies
    • 11.3.1 List of Key Emerging Companies
  • 11.4 Competitive Factors and Strategies
    • 11.4.1 Increasing strategic collaborations and product launch
    • 11.4.2 Strategic Government initiatives which include collaborations
    • 11.4.3 Competitors increased PV awareness program
    • 11.4.4 Competitors increased collaboration and outsourcing of operations
    • 11.4.5 Consolidation Trends
  • 11.5 Healthcare Companies Using Pharmacovigilance Services
    • 11.5.1 Potential Customers
    • 11.5.2 Notable Cases
      • 11.5.2.1 Case Study 1
      • 11.5.2.1.1 Case Study 1
      • 11.5.3.1.2 Case Study 2
      • 11.5.2.2 Case Study 2
      • 11.5.2.3 Case Study 3
      • 11.5.3.4 Case Study 4
    • 11.5.3 Key Focus areas for the pharmaceutical/healthcare companies
      • 11.5.3.1 Adoption of technological advancements in life sciences industry
      • 11.5.3.2 Published survey insights - related to adoption of pharmacovigilance automation

Chapter 12 Competitive Landscape

  • 12.1 Company Profiles
    • 12.1.1 ACCENTURE
      • 12.1.1.1 Company overview
      • 12.1.1.2 Service benchmarking
      • 12.1.1.3 Financial performance
      • 12.1.1.4 Strategic initiatives
      • 12.1.1.5 SWOT Analysis
    • 12.1.2 CLINQUEST GROUP B.V. (LINICAL AMERICAS)
      • 12.1.2.1 Company overview
      • 12.1.2.2 Service benchmarking
      • 12.1.2.3 Financial performance
      • 12.1.2.4 Strategic initiatives
      • 12.1.2.5 SWOT Analysis
    • 12.1.3 IQVIA Inc.
      • 12.1.3.1 Company overview
      • 12.1.3.2 Service benchmarking
      • 12.1.3.3 Financial performance
      • 12.1.3.4 Strategic initiatives
      • 12.1.3.5 SWOT Analysis
    • 12.1.4 COGNIZANT
      • 12.1.4.1 Company overview
      • 12.1.4.2 Service benchmarking
      • 12.1.4.3 Financial performance
      • 12.1.4.4 Strategic initiatives
      • 12.1.4.5 SWOT Analysis
    • 12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 12.1.5.1 Company overview
      • 12.1.5.2 Service benchmarking
      • 12.1.5.3 Financial performance
      • 12.1.5.4 Strategic initiatives
      • 12.1.5.5 SWOT Analysis
    • 12.1.6 IBM
      • 12.1.6.1 Company overview
      • 12.1.6.2 Service benchmarking
      • 12.1.6.3 Financial performance
      • 12.1.6.4 Strategic initiatives
      • 12.1.6.5 SWOT Analysis
    • 12.1.7 ARISGLOBAL
      • 12.1.7.1 Company Overview
      • 12.1.7.2 Service Benchmarking
      • 12.1.7.3 Financial Performance
      • 12.1.7.4 Strategic Initiatives
      • 12.1.7.5 SWOT Analysis
    • 12.1.8 ICON PLC.
      • 12.1.8.1 Company Overview
      • 12.1.8.2 Service Benchmarking
      • 12.1.8.3 Financial Performance
      • 12.1.8.4 Strategic Initiatives
      • 12.1.8.5 SWOT Analysis
    • 12.1.9 CAPGEMINI
      • 12.1.9.1 Company Overview
      • 12.1.9.2 Service Benchmarking
      • 12.1.9.3 Financial Performance
      • 12.1.9.4 Strategic Initiatives
      • 12.1.9.5 SWOT Analysis
    • 12.1.10 ITCLINICAL
      • 12.1.10.1 Company Overview
      • 12.1.10.2 Service Benchmarking
      • 12.1.10.3 Financial Performance
      • 12.1.10.4 Strategic Initiatives
      • 12.1.10.5 SWOT Analysis
    • 12.1.11 TAKE SOLUTIONS LIMITED
      • 12.1.11.1 Company Overview
      • 12.1.11.2 Service Benchmarking
      • 12.1.11.3 Financial Performance
      • 12.1.11.4 Strategic Initiatives
      • 12.1.11.5 SWOT Analysis
    • 12.1.12 PAREXEL INTERNATIONAL CORPORATION.
      • 12.1.12.1 Company Overview
      • 12.1.12.2 Service Benchmarking
      • 12.1.12.3 Financial Performance
      • 12.1.12.4 Strategic Initiatives
      • 12.1.12.5 SWOT Analysis
    • 12.1.13 BIOCLINICA, INC.
      • 12.1.13.1 Company overview
      • 12.1.13.2 Service benchmarking
      • 12.1.13.3 Financial performance
      • 12.1.13.4 Strategic initiatives
      • 12.1.13.5 SWOT Analysis
    • 12.1.14 WIPRO
      • 12.1.14.1 Company Overview
      • 12.1.14.2 Service Benchmarking
      • 12.1.14.3 Financial Performance
      • 12.1.14.4 Strategic Initiatives
      • 12.1.14.5 SWOT Analysis
    • 12.1.15 UNITED BIOSOURCE LLC
      • 12.1.15.1 Company Overview
      • 12.1.15.2 Service Benchmarking
      • 12.1.15.3 Financial Performance
      • 12.1.15.4 Strategic initiatives
      • 12.1.15.5 SWOT Analysis
    • 12.1.16 FMD K&L (CLINCHOICE)
      • 12.1.16.1 Company Overview
      • 12.1.16.2 Service Benchmarking
      • 12.1.16.3 Financial performance
      • 12.1.16.4 Strategic initiatives
      • 12.1.16.5 SWOT Analysis

Chapter 13 Winning Strategies

  • 13.1 Key Winning/Scoring Criteria
    • 13.1.1 By Categories
      • 13.1.1.1 Pharmaceuticals
      • 13.1.1.2 Biotech companies
      • 13.1.1.3 Medical device companies
  • 13.2 Key Vendor Selection Factors
    • 13.2.1 By Category
    • 13.2.2 By Company Size
      • 13.2.2.1 Key Takeaways

Chapter 14 Switching Cost Analysis

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation
  • Table 3 Types of ADRs
  • Table 4 Adverse Drug Events (ADEs) in hospitals
  • Table 5 Pharmacovigilance outsourcing services insights
  • Table 6 List of regulations, by country
  • Table 7 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
  • Table 8 Case management costing by year
  • Table 9 Price by case processing volume
  • Table 10 Subscription services for medical manuscript writing
  • Table 11 Total literature searches (2013-2022)
  • Table 12 Instances of failed phase I clinical trials for COVID-19 vaccine
  • Table 13 Recruiting phase II clinical trials for oncology
  • Table 14 Outsourcing trend observed in pharmaceutical companies
  • Table 15 Recent Market Events
  • Table 16 List of Major Deals & Acquisitions
  • Table 17 List of key distributors and channel partners
  • Table 18 List of key emerging companies'/technology disruptors/innovators
  • Table 19 North America Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 20 North America Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 21 North America Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 22 North America Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 U.S. Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 24 U.S. Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 25 U.S. Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Canada Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 27 Canada Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 28 Canada Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Europe Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 30 Europe Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 31 Europe Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 32 Europe Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Germany Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 34 Germany Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 35 Germany Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 36 UK Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 37 UK Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 38 UK Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 France Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 40 France Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 41 France Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Italy Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 43 Italy Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 44 Italy Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Spain Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 46 Spain Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 47 Sapin Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Denmark Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 49 Denmark Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 50 Denmark Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 Sweden Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 52 Sweden Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 53 Sweden Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Norway Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 55 Norway Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 56 Norway Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Japan Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 62 Japan Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 63 Japan Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 64 China Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 65 China Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 66 China Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 67 India Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 68 India Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 69 India Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 70 Australia Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 71 Australia Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 72 Australia Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 South Korea Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 74 Thailand Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 75 Thailand Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 76 Thailand Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 77 Latin America Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 78 Latin America Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 79 Latin America Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 80 Latin America Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 81 Brazil Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 82 Brazil Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 83 Brazil Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 84 Mexico Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 85 Mexico Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 86 Mexico Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Argentina Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 88 Argentina Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 89 Argentina Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 90 MEA Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
  • Table 91 MEA Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 92 MEA Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 93 MEA Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 94 South Africa Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 95 South Africa Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 96 South Africa Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 97 Saudi Arabia Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 98 Saudi Arabia Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 99 Saudi Arabia Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 100 UAE Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 101 UAE Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 102 UAE Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
  • Table 103 Kuwait Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
  • Table 104 Kuwait Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
  • Table 105 Kuwait Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pharmacovigilance market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Primary interviews in North America
  • Fig. 6 Primary interviews in Europe
  • Fig. 7 Primary interviews in APAC
  • Fig. 8 Primary interviews in Latin America
  • Fig. 9 Primary interviews in MEA
  • Fig. 10 Market research approaches
  • Fig. 11 Value-chain-based sizing & forecasting
  • Fig. 12 QFD modeling for market share assessment
  • Fig. 13 Market formulation & validation
  • Fig. 14 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
  • Fig. 15 Market Snapshot
  • Fig. 16 Segment Snapshot (Product Life Cycle & Service Provider)
  • Fig. 17 Segment Snapshot (Type & Therapeutic Area)
  • Fig. 18 Segment Snapshot (Process Flow & End Use))
  • Fig. 19 Competitive Landscape Snapshot
  • Fig. 20 Penetration & growth prospect mapping
  • Fig. 21 Pharmacovigilance market dynamics
  • Fig. 22 Porter's five force model
  • Fig. 23 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 24 Pharmacovigilance & Patient Safety Services - Product Life Cycle
  • Fig. 25 PV department
  • Fig. 26 PV organization structure
  • Fig. 27 Estimated budget allocation of drug safety activities at global and country-level
  • Fig. 28 Comparison between estimated global and country-level drug safety budget allocation
  • Fig. 29 Average % of drug safety budget contributed by function at a global level
  • Fig. 30 Pharmacovigilance system cost for small-sized firms and larger-sized firms
  • Fig. 31 Clinical trial cost by phase (%)
  • Fig. 32 Selected clinical trials costs based on technology
  • Fig. 33 Estimated cost of developing therapeutic medical device in the U.S.
  • Fig. 34 The average monthly cost of illness due to ADRs
  • Fig. 35 Medical Writers Employers by Industry
  • Fig. 36 Trending topics on social media (2017)
  • Fig. 37 ADR detection and from social media data
  • Fig. 38 Common literature automation tool flow
  • Fig. 39 Automation processes in PV
  • Fig. 40 Deterrents to Leveraging the Cloud (Oracle Survey)
  • Fig. 41 The three-step process to compute signal statistics from search log using big data
  • Fig. 42 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
  • Fig. 43 Pharma & Biotech R&D expense growth, 2020 (%)
  • Fig. 44 Medical writing market outlook, 2022 (USD Million)
  • Fig. 45 Medical writing market, 2018 - 2030 (USD Million)
  • Fig. 46 Global medical safety review market, 2018 - 2030 (USD Million)
  • Fig. 47 Pharmacovigilance market: Product life cycle movement analysis
  • Fig. 48 Pharmacovigilance market product life cycle dashboard
  • Fig. 49 Global Preclinical market, 2018 - 2030 (USD Million)
  • Fig. 50 Global Phase I market, 2018 - 2030 (USD Million)
  • Fig. 51 Global Phase II market, 2018 - 2030 (USD Million)
  • Fig. 52 Global Phase III market, 2018 - 2030 (USD Million)
  • Fig. 53 Adverse events reported in FAERS system, 2019 - 2022
  • Fig. 54 Global Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 55 Pharmacovigilance market: Service provider movement analysis
  • Fig. 56 Pharmacovigilance Service provider dashboard
  • Fig. 57 Global In-house market, 2018 - 2030 (USD Million)
  • Fig. 58 Global contract outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 59 Pharmacovigilance market: Type movement analysis
  • Fig. 60 Pharmacovigilance type dashboard
  • Fig. 61 Global spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 62 Global intensified ADR reporting market, 2018 - 2030 (USD Million)
  • Fig. 63 Global targeted spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 64 Global CEM market, 2018 - 2030 (USD Million)
  • Fig. 65 Global EHR mining market, 2018 - 2030 (USD Million)
  • Fig. 66 Pharmacovigilance market: Process flow movement analysis
  • Fig. 67 Pharmacovigilance market process flow dashboard
  • Fig. 68 Global case data management market, 2018 - 2030 (USD Million)
  • Fig. 69 Global case logging market, 2018 - 2030 (USD Million)
  • Fig. 70 Global case data analysis market, 2018 - 2030 (USD Million)
  • Fig. 71 Global medical reviewing and reporting market, 2018 - 2030 (USD Million)
  • Fig. 72 Global signal detection market, 2018 - 2030 (USD Million)
  • Fig. 73 Global adverse event logging market, 2018 - 2030 (USD Million)
  • Fig. 74 Global adverse event analysis market, 2018 - 2030 (USD Million)
  • Fig. 75 Global adverse event review & reporting market, 2018 - 2030 (USD Million)
  • Fig. 76 Global risk management system market, 2018 - 2030 (USD Million)
  • Fig. 77 Global Risk Evaluation System market, 2018 - 2030 (USD Million)
  • Fig. 78 Global risk mitigation system market, 2018 - 2030 (USD Million)
  • Fig. 79 Pharmacovigilance market: Therapeutic area movement analysis
  • Fig. 80 Pharmacovigilance market therapeutic area dashboard
  • Fig. 81 Global oncology market, 2018 - 2030 (USD Million)
  • Fig. 82 Global neurology market, 2018 - 2030 (USD Million)
  • Fig. 83 Global cardiology market, 2018 - 2030 (USD Million)
  • Fig. 84 Global respiratory systems market, 2018 - 2030 (USD Million)
  • Fig. 85 Global others market, 2018 - 2030 (USD Million)
  • Fig. 86 Pharmacovigilance market: End use movement analysis
  • Fig. 87 Pharmacovigilance market end use dashboard
  • Fig. 88 Global pharmaceuticals market, 2018 - 2030 (USD Million)
  • Fig. 89 Global biotechnology companies' market, 2018 - 2030 (USD Million)
  • Fig. 90 Global medical device manufacturers market, 2018 - 2030 (USD Million)
  • Fig. 91 Global others market, 2018 - 2030 (USD Million)
  • Fig. 92 Regional market place: Key takeaways
  • Fig. 93 North America pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 94 U.S. key country dynamics (Part 1)
  • Fig. 95 U.S. key country dynamics (Part 2)
  • Fig. 96 U.S. pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 97 Canada key country dynamics (Part 1)
  • Fig. 98 Canada key country dynamics (Part 2)
  • Fig. 99 Canada pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 100 Europe pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 101 UK key country dynamics (Part 1)
  • Fig. 102 UK key country dynamics (Part 2)
  • Fig. 103 UK pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 104 Germany key country dynamics (Part 1)
  • Fig. 105 Germany key country dynamics (Part 2)
  • Fig. 106 Germany pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 107 France key country dynamics (Part 1)
  • Fig. 108 France key country dynamics (Part 2)
  • Fig. 109 France pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 110 Italy key country dynamics (Part 1)
  • Fig. 111 Italy key country dynamics (Part 2)
  • Fig. 112 Italy pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 113 Spain key country dynamics (Part 1)
  • Fig. 114 Spain key country dynamics (Part 2)
  • Fig. 115 Spain pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 116 Russia key country dynamics
  • Fig. 117 Russia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 118 Denmark key country dynamics (Part 1)
  • Fig. 119 Denmark key country dynamics (Part 2)
  • Fig. 120 Denmark pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 Norway key country dynamics (Part 1)
  • Fig. 122 Norway key country dynamics (Part 2)
  • Fig. 123 Norway pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 124 Sweden key country dynamics (Part 1)
  • Fig. 125 Sweden key country dynamics (Part 2)
  • Fig. 126 Sweden pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 127 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 128 Japan pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 129 China key country dynamics (Part 1)
  • Fig. 130 China key country dynamics (Part 2)
  • Fig. 131 China pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 132 India key country dynamics (Part 1)
  • Fig. 133 India key country dynamics (Part 2)
  • Fig. 134 India pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 135 Australia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 136 Thailand key country dynamics (Part 1)
  • Fig. 137 Thailand key country dynamics (Part 2)
  • Fig. 138 Thailand pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 139 South Korea pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 140 Latin America pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 141 Brazil pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 142 Mexico key country dynamics
  • Fig. 143 Mexico pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 144 Argentina pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 145 MEA pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 146 South Africa pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 147 Saudi Arabia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 148 UAE key country dynamics (Part 1)
  • Fig. 149 UAE key country dynamics (Part 2)
  • Fig. 150 UAE pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 151 Kuwait pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 152 Market participant categorization
  • Fig. 153 Company market position analysis
  • Fig. 154 Estimated company market share analysis, 2022 (%)
  • Fig. 155 SWOT - Accenture
  • Fig. 156 SWOT - Linical Americas
  • Fig. 157 SWOT - IQVIA
  • Fig. 158 SWOT - Cognizant
  • Fig. 159 SWOT - Laboratory Corporation of America Holdings
  • Fig. 160 SWOT - IBM Corporation
  • Fig. 161 SWOT - ArisGlobal
  • Fig. 162 SWOT - ICON plc
  • Fig. 163 SWOT - Capgemini
  • Fig. 164 SWOT - ITClinical
  • Fig. 165 SWOT - Take Solutions
  • Fig. 166 SWOT - Parexel International Corporation
  • Fig. 167 SWOT - Clario
  • Fig. 168 SWOT - Wipro
  • Fig. 169 SWOT - United BioSource LLC
  • Fig. 170 SWOT - FMD K&L
  • Fig. 171 Commonly outsourced PV activities
  • Fig. 172 Vendor selection criteria